Clinical Attribute

FDA Considers Noninvasive Endpoint for MASH Trials, Boosts Biotech Shares

2 weeks ago talkbio0Tagged Altimmune, Biological Markers, Clinical Trials, Inventiva, Liver diseases, Madrigal Pharmaceuticals, MASH, Noninvasive Endpoint, stocks, United States Food and Drug Administration, Viking Therapeutics

FDA; noninvasive endpoint; liver disease; MASH; clinical trials; biomarker; biotech stocks; Madrigal Pharmaceuticals; Viking Therapeutics; Inventiva; Altimmune

Personalizing Metabolic Care with Digital Twins: Recent Developments

2 weeks ago talkbio0Tagged Administration occupational activities, Aortic Valve Insufficiency, Biological Markers, Diabetes, digital twins, Glucagon-Like Peptide 1, Health care facility, metabolic health, Obesity, Precision Medicine, real-time guidance, Reversal, Twin Health

digital twins; metabolic health; AI healthcare; personalized medicine; biomarkers; diabetes management; obesity reversal; real-time guidance; GLP-1; Twin Health

AI, Media and the Evolution of Omnichannel in Healthcare Marketing — Ray Rosti on Episode 3 of The Next Marketing with HJ

1 month ago talkbio0Tagged Aortic Valve Insufficiency, Automation, Biomechanical compliance, Communications Media, connected journeys, content intelligence, Doceree, Engaged to be married, Health Care Market, Hereditary Coproporphyria, Klick Media, Measurement, omnichannel, Optimization, personalization, Pharma, Privacy, Region of interest:Presence or Identity:Point in time:*:Nominal

AI in healthcare marketing; omnichannel; first‑party data; content intelligence; media optimization; privacy and compliance; measurement and ROI; pharma marketing; Klick Media; Doceree; HCP engagement; personalization; automation; connected journeys

Roche Doubles Down on Alzheimer’s with Next-Gen Amyloid-Lowering Drug Trontinemab

1 month ago talkbio0Tagged Alzheimer 's disease, amyloid-lowering drug, Biological Markers, Brainshuttle, Drug Development, Interventional procedure, Phase 3 Clinical Trials, Roche (company), TRONTIER, Trontinemab

Roche; Alzheimer’s disease; trontinemab; amyloid-lowering drug; Brainshuttle; Phase III trial; TRONTIER studies; drug development; biomarkers; early intervention

Advancements in Predicting Tumor Response and Expanding Therapy Eligibility Using Epigenomic Biomarkers

2 months ago talkbio0Tagged Biological Markers, Diagnostics, DNA Methylation, Epigenomics, personalized cancer therapy, Prediction, tumor response

epigenomic biomarkers; tumor response prediction; personalized cancer therapy; DNA methylation; AI-driven diagnostics

ALTO-203 Misses Depression Endpoint but Shows Positive Biomarker and Cognitive Signals

3 months ago talkbio0Tagged ALTO-203, Attention, Biological Markers, development aspects, drug activity, Electroencephalography, Neuroscience discipline, theta/beta ratio, Wakefulness, William Blair

ALTO-203; Alto Neuroscience; Phase 2 trial; major depressive disorder; EEG biomarkers; theta/beta ratio; attention; wakefulness; William Blair; drug activity; future development

Recent Developments in Immune Profiling for Early Immuno-Oncology Trials

3 months ago talkbio0Tagged Aortic Valve Insufficiency, Biological Markers, Clinical Trials, Discover, immune profiling, immuno-oncology, Immunotherapy, microenvironment, multi-omic strategies, Neoplasms, Precision Medicine, spatial proteomics

immune profiling; immuno-oncology; clinical trials; AI in immunotherapy; multi-omic strategies; tumor microenvironment; spatial proteomics; biomarker discovery; personalized medicine

Roche Advances Prasinezumab Into Phase III Trials for Parkinson’s Despite Mixed Phase II Results

3 months ago talkbio0Tagged alpha-synuclein antibody, Biological Markers, Clinical Trials, disease-modifying treatment, PADOVA study, Parkinson 's disease, Pasadena, Phase 3 Clinical Trials, Prasinezumab, Prothena, Roche (company)

Roche; prasinezumab; Parkinson’s disease; Phase III trial; clinical trials; alpha-synuclein antibody; Prothena; PADOVA study; PASADENA study; biomarker; disease-modifying treatment

NewAmsterdam Reports Cholesterol Drug Obicetrapib May Slow Alzheimer’s Biomarker Buildup

3 months ago talkbio0Tagged Alzheimer 's disease, Apolipoprotein E4, Biological Markers, CETP, cholesterol ester transfer protein inhibitor, NewAmsterdam Pharma, Obicetrapib, p-tau217, Phase 3

NewAmsterdam Pharma; obicetrapib; cholesterol ester transfer protein inhibitor (CETP); Alzheimer’s disease biomarkers; p-tau217; ApoE4; BROADWAY trial; Phase 3

Regenxbio Reports Consistent One-Year Benefit for DMD Gene Therapy RGX-202

3 months ago talkbio0Tagged AFFINITY DUCHENNE trial, Biological Markers, Clinical Trials, Functional, gene therapy, Muscular Dystrophy, Duchenne, Phase III, Regenxbio, SLC6A8 Inhibitor RGX-202

Regenxbio; DMD; Duchenne muscular dystrophy; RGX-202; gene therapy; AFFINITY DUCHENNE trial; clinical trial; microdystrophin; biomarker; phase I/II; functional data